Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data (Podcasts)
Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025
The Latest Approaches to the Care of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas Including the Use of Bispecific Antibodies
This CME activity will provide hematologists and oncologists with practical, case-based insights into the management of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, with a special focus on follicular lymphoma (R/R FL). Expert faculty will review prognostic tools and clinical features, including early relapse, to guide risk stratification and inform treatment planning. The program will highlight the role of bispecific antibody therapies, with an emphasis on integrating clinical trial data into personalized care strategies. Special attention will be given to proactive recognition, grading, and management of toxicities, particularly cytokine release syndrome, as well as best practices in infection prophylaxis and monitoring. Through didactic discussion, illustrative case study, and whiteboard animation, learners will gain strategies to optimize outcomes and safely implement bispecific therapies for patients with R/R FL.
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026
The ACTIVATE Initiative:
Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies
These podcasts are designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma. Additionally, healthcare professionals will be able to understand the importance of patient advocacy as we converse with a patient about their cancer diagnosis and treatment.
RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Monday, April 13, 2026
3:00 p.m. – 4:00 p.m. ET
Please note this TeleECHO program is 3:00 p.m. Eastern, 2:00 p.m. Central, 1:00 p.m. Mountain and 12:00 p.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Monday, May 18, 2026
12:00 p.m. – 1:00 p.m. ET
Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Wednesday, May 13, 2026
3:00 p.m. – 4:00 p.m. ET
Please note this TeleECHO program is 3:00 p.m. Eastern, 2:00 p.m. Central, 1:00 p.m. Mountain and 12:00 p.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Tuesday, May 5, 2026
1:00 p.m. – 2:00 p.m. ET
Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Wednesday, April 29, 2026
12:00 p.m. – 1:00 p.m. ET
Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Thursday, April 23, 2026
1:00 p.m. – 2:00 p.m. ET
Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Wednesday, April 8, 2026
7:00 p.m. – 6:00 p.m. ET
Please note this TeleECHO program is 7:00 p.m. Eastern, 6:00 p.m. Central, 5:00 p.m. Mountain and 4:00 p.m. Pacific.